all report title image
  • Published On : Oct 2022
  • Code : CMI5275
  • Industry : Biotechnology
  • Pages : 170
  • Formats :

The global human embryonic stem cells market was valued at US$ 1,058.9 Mn in 2021 and is forecast to reach a value of US$ 1,955.3 Mn by 2028 at a CAGR of 9.2% between 2022 and 2028. The global human embryonic stem cells market is experiencing strong growth due to the increase in focus on the development of stem cell therapies across the globe. Moreover, rise in prevalence of cardiac & malignant diseases and increase in demand for regenerative medicines across the globe is expected to boost growth of the market. However, high cost of the procedure and stringent regulatory guidelines and ethical issues are major factors expected to hamper the growth of the human embryonic stem cells market.

Global Human Embryonic Stem Cells Market: Regional Insights

Based on geography, the global human embryonic stem cells market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period owing to the high prevalence of cardiac and malignant diseases and increase in focus in the development of cell line based therapies in this region, especially in the U.S. For instance, human embryonic stem cells (hESC) have a high potential for use in treatment and may become a standard of care for these diseases. Heart disease is one of the leading cause of death in the United States. According to the Centers for Disease Control and Prevention (CCD), one person dies every 34 seconds from heart disease in the U.S.

Asia Pacific is also expected to witness significant growth in the global human embryonic stem cells market owing to the rising burden of chronic diseases and government support for hESC research in the region. For instance, in February 2020, the Global Institute of Stem Cell Therapy and Research (GIOSTAR) inaugurated a new stem cell and cancer research and therapy centre in India. This facility represents the latest milestone in global expansion efforts spearheaded by GIOSTAR in India, Mexico, the United States, and numerous other countries. It is the most recent in a series of hospitals being launched throughout the country.

Figure 1. Global Human Embryonic Stem Cells Market Share (%), by Region, 2021

Human Embryonic Stem Cells  | Coherent Market Insights

Global Human Embryonic Stem Cells Market Drivers:

Increase in incidence/prevalence of cardiac and malignant diseases across the world is expected to augment growth of the global human embryonic stem cells market over the forecast period. Human embryonic stem cells (hESC) have high potential for use in treatment and may become a standard of care for cardiac/malignant diseases. According to the World Health Organization (WHO), cardiac diseases are one of the leading cause of death worldwide, taking an estimated 17.9 million lives each year; an estimated 32% of all deaths worldwide.

Rising demand for regenerative medicines across the globe is expected to boost growth of the global human embryonic stem cells market over the forecast period. For instance, in February 2022, in an effort to support the research and development (R&D) in regenerative medicine in the country, the Government of India has helped setting up state-of-the-art stem cell research facilities in 40 premier health research and educational institutions. It has also spent around Rs. 8.13 crore through Indian Council of Medical Research (ICMR) under certain projects.

Global Human Embryonic Stem Cells Market Opportunities:

Favorable government initiatives or rise in support from governments or private organisations are expected to offer lucrative growth opportunities for players in the global human embryonic stem cells market. For instance, in June 2022, a global stem cell research collaboration that will develop new treatments for cancer, diabetes, and cardiovascular diseases has been launched at the Murdoch Children’s Research Centre (MCRI). The center is made possible through a record stem cell drug grant of €300 million over 10 years from the Novo Nordisk Foundation.

Increase in focus on the development of stem cell therapies is expected to provide significant growth opportunities for players in the human embryonic stem cells market. For instance, the embryonic stem cells are the future of the medicines. These cells can be used for therapeutic purposes. In January 2022, Cellino Biotech raised about US$ 80 million in a Series A financing round. Cellino Biotech planned to expand access to stem cell-based therapies by building the first autonomous human cell foundry in 2025.

CMI table icon

Human Embryonic Stem Cells Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 1,152.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2022 to 2028 CAGR: 9.2% 2028 Value Projection: US$ 1,955.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product: Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, and Toxicology Testing
Companies covered:

Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, Merck KgaA, PeproTech Inc., Astellas Pharma Inc., Thermo Fisher Scientific, Lineage Cell Therapeutics Inc., and STEMCELL Technologies Inc., among others

Growth Drivers:
  • High prevalence of cardiac and malignant diseases
  • Increase in demand for regenerative medicines across the globe
Restraints & Challenges:
  • High cost of the procedure
  • Stringent regulatory guidelines and ethical issues

Global Human Embryonic Stem Cells Market Trends:

Different types of stem cells are used for therapeutic purposes. With several applications in the clinical stage for various diseases, these cells are being widely explored by a large number of pharmaceutical and biopharmaceutical companies worldwide. Stem cell biology research will show better growth due to the rise in incidence of cardiovascular and malignant diseases such as cancer, cardiac disease, diabetes, and others, and this trend is expected to continue over the forecast period, driving the growth of the market.

With the success in human embryonic stem cells and technological advancements in the field of stem cell, the number of clinical trials performed is also increasing across the globe. The AI (artificial intelligence) techniques are useful for optimizing the clinical trials of new/innovative embryonic stem cells and predictive models. Researchers worldwide are using AI to evaluate stem cell-based therapies for cardiovascular diseases, eye related diseases, and immune system related diseases, and this trend is expected to continue during the forecast period.

Global Human Embryonic Stem Cells Market Restraints:

Stringent regulatory guidelines and ethical issues are expected to hamper growth of the global human embryonic stem cells market. The National Academies urged all institutions conducting such research to establish oversight committees to ensure that the guidelines will be followed. According to the National Research Council and Institute of Medicine, guidelines are intended to enhance integrity of privately funded hESC research by encouraging responsible practices. In India, it takes around a year to get the Drugs Control General of India (DCGI)’s approval for conducting any type of stem cell clinical trial.

High cost of the procedure is expected to hinder growth of the global human embryonic stem cells market. For instance, cost of stem cell manufacturing and banking is significantly high. Stem cell therapy costs can range anywhere from US$ 5000 - US$ 50,000. However, treatment cost will vary dramatically depending on a variety of different factors. The cost of the media used for human embryonic stem cell manufacturing is even more costly. Medium of Thermo Fischer cost around INR 32,954 for just 500ml. The cost of manufacturing hESC act as a barrier to the growth of the human embryonic stem cells market.

Figure 2. Global Human Embryonic Stem Cells Market Share (%), by Application, 2021

Human Embryonic Stem Cells  | Coherent Market Insights

Global Human Embryonic Stem Cells Market Segmentation:

The human embryonic stem cells market report is segmented into Product and Geography.

Based on Product, the market is segmented into Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, and Toxicology Testing. Out of which, Regenerative Medicine Segment is expected to dominate the human embryonic stem cells market during the forecast period and this is attributed to the rising demand for regenerative medicines across the world. hESC has great promise for regenerative medicine and can lead to the rare treatment of stroke, diabetes, neural diseases, myocardial infarction, and other prominent human diseases.

Stem Cell Biology Research Segment is also expected to witness significant growth over the forecast period and this is owing to the increase in stem cell biology research. Stem cell biology research will show better growth, owing to the increase in prevalence of cardiac and malignant diseases such as Cancer, Parkinson's disease, and Others.

Global Human Embryonic Stem Cells Market: Key Developments

In July 2020, Thermo Fisher Scientific Inc. and QIAGEN N.V. entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN.

In January 2020, Astellas Pharma Inc. and Adaptimmune Therapeutics Plc. entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.

Global Human Embryonic Stem Cells Market: Key Companies Insights

The global human embryonic stem cells market is highly competitive. This is attributed to the increase in prevalence of cardiac and malignant diseases, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global human embryonic stem cells market are Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, Merck KgaA, PeproTech Inc., Astellas Pharma Inc., Thermo Fisher Scientific, Lineage Cell Therapeutics Inc., and STEMCELL Technologies Inc., among others.

*Definition: Embryonic stem cells (ESC) are pluripotent cells which give rise to all somatic cell types in the embryo. Human embryonic stem cells (hESC) have a high potential for use in treatment and may become a standard of care for various cardiac and malignant diseases. The use of human embryos for research on embryonic stem (ES) cells is currently high on the ethical and political agenda in many countries.

Stem cells are biological cells that can differentiate into other types of cells, and are used for therapeutic purposes. Recent developments or advancements have paved the way for a plethora of potential therapies, due to which, therapies involving human embryonic stem cells are being widely adopted worldwide. Human embryonic stem cells have emerged as attractive candidates for cell-based therapies that are capable of restoring lost cell and tissue function. Furthermore, human embryonic stem cells (hESC) have a high potential for use in treatment and may become a standard of care for cardiac and malignant diseases.

Market Dynamics:

Rise in incidence of cardiac and malignant diseases, increase in focus on the development of stem cell-based therapies, growing demand for regenerative medicines, and increasing support from government and private organizations are major factors expected to drive growth of the global human embryonic stem cells market during the forecast period.

For instance, in April 2021, Vertex Pharmaceuticals received the United States Food and Drug Administration (FDA) Fast Track Designation for VX-880, and the company initiated a clinical trial for VX-880 in patients who have type 1 diabetes with severe hypoglycemia and impaired hypoglycemic awareness.

In February 2020, Global Institute of Stem Cell Therapy and Research (GIOSTAR) announced the inauguration of a new stem cell / cancer research and therapy center in India. This facility represents the latest milestone in global expansion efforts spearheaded by GIOSTAR in India, Mexico, the United States, and numerous other countries.

Key features of the study:

  • The report provides in-depth analysis of the global human embryonic stem cells market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global human embryonic stem cells market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, Merck KgaA, PeproTech Inc., Astellas Pharma Inc., Thermo Fisher Scientific, Lineage Cell Therapeutics Inc., and STEMCELL Technologies Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global human embryonic stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human embryonic stem cells market.

Detailed Segmentation:

  • Global Human Embryonic Stem Cells Market, By Product:
    • Regenerative Medicine
    • Stem Cell Biology Research
    • Tissue Engineering
    • Toxicology Testing
  • Global Human Embryonic Stem Cells Market, By Geography:
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World
  • Company Profiles:
    • Takara Bio Inc.
    • ViaCyte Inc.
    • PromoCell GmbH
    • Merck KgaA
    • PeproTech Inc.
    • Astellas Pharma Inc.
    • Thermo Fisher Scientific
    • Lineage Cell Therapeutics Inc.
    • STEMCELL Technologies Inc.

Frequently Asked Questions

The global human embryonic stem cells market size is estimated to be valued at US$ 1,152.2 Million in 2022 and is expected to exhibit a CAGR of 9.2% between 2022 and 2028.
High prevalence of cardiac and malignant diseases and high demand for regenerative medicines across the globe is fueling the growth of the market.
The regenerative medicine segment is the leading application segment in the market.
High cost of the procedure and stringent regulatory guidelines & ethical issues are major factors restraining growth of the market.
Major players operating in the market are Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, Merck KgaA, PeproTech Inc., Astellas Pharma Inc., Thermo Fisher Scientific, Lineage Cell Therapeutics Inc., and STEMCELL Technologies Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo